C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy

Kidney International

Volumn 68, Issue 2, 2005, Pages 773-778

  Friedman, Allon N ^a   Hunsicker, Lawrence G ^b   Selhub, Jacob ^b   Bostom, Andrew G ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

Arteriosclerosis; C reactive protein; Cardiovascular; Diabetes; Irbesartan Diabetic Nephropathy Trial; Nephropathy

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; IRBESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; RECURRENT DISEASE; RISK FACTOR; UNIVARIATE ANALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INCIDENCE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TETRAZOLES;

EID: 26944477470     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00456.x     Document Type: Article

References (27)

1. WILLERSON JT, RIDKER PM: Inflammation as a cardiovascular risk factor. Circulation 109 (Suppl 1):S2-S10, 2004
2. RIDKER PM, CUSHMAN M, STAMPFER MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
3. RIDKER PM, BURING JE, SHIH J, et al: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733, 1998
4. RIDKER PM, RIFAI N, PFEFFER MA, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98:839-844, 1998
5. VAN DER MEER IM, DE MAAT MP, KILIAAN AJ, et al: The value of C-reactive protein in cardiovascular risk prediction: The Rotterdam Study. Arch Intern Med 163:1323-1328, 2003
6. SARNAK MJ, LEVEY AS, SCHOOLWERTH AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169, 2003
7. HAFFNER SM, LEHTO S, RONNEMAA T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
8. VASAN RS, SULLIVAN LM, ROUBENOFF R, et al: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 107:1486-1491, 2003
9. RODBY RA, ROHDE RD, CLARKE WR et al, FOR THE COLLABORATIVE STUDY GROUP. The Irbesartan Type II Diabetic Nephropathy Trial: Study design and baseline patient characteristics. Nephrol Dial Transplant 15:487-497, 2000.
10. LEWIS EJ, HUNSICKER LG, CLARKE WR et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
11. BERL T, HUNSICKER LG, LEWIS JB, et al: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542-549, 2003
12. ANDERSON P, GILL R: Cox's regression model for counting precesses: A large sample study. Ann Stat 10:1100-1120, 1982
13. LEE E, WEI L, AMATO D: Cox-type regerssion analysis for large number of small groups of correlated failure time observations, in Survival Analysis, State of the Art, edited by Klein J, Goel P, The Netherlands. Kluwer Academic Publishers, 1992, pp 237-247
14. GREENFIELD JR, SAMARAS K, JENKINS AB, et al: Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 22:3022-3028, 2004
15. ORTEGA O, RODRIGUEZ I, GALLAR P, et al: Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17:1105-1109, 2002
16. SCHULZE MB, RIMM EB, LI T, et al: C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27:889-894, 2004
17. CURB JD, ABBOTT RD, RODRIGUEZ BL, et al: C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 107:2016-2020, 2003
18. MOJIMINIYI OA, ABDELLA N, MOUSSA MA, et al: Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 58:37-44, 2002
19. SAKKINEN P, ABBOTT RD, CURB JD, et al: C-reactive protein and myocardial infarction. J Clin Epidemiol 55:445-451, 2002
20. DANESH J, WHEELER JG, HIRSCHFIELD GM, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397, 2004
21. TALL AR: C-reactive protein reassessed. N Engl J Med 350:1450-1452, 2004
22. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
23. FRIEDMAN AN, HUNSICKER LG, SELHUB J, et al: Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. Atherosclerosis 172:121-125, 2004
24. FRIEDMAN AN, BOSTOM AG, SELHUB J, et al: The kidney and homocysteine metabolism. J Am Soc Nephrol 12:2181-2189, 2001
25. CASTANEDA C, GORDON PL, PARKER RC, et al: Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43:607-616, 2004
26. RIDKER PM, RIFAI N, PFEFFER MA, et al: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230-235, 1999
27. BAUMGARTEN G, KNUEFERMANN P, MANN DL: Cytokines as emerging targets in the treatment of heart failure. Trends Cardiovasc Med 10:216-223, 2000